HOME
Business Operation
About us
News Releases

Home News Releases FDA approved Phase I Study of IMF-001 in US.

FDA approved Phase I Study of IMF-001 in US.

2010/09/23

Categories

News Releases

Post navigation

Previous Post ImmunoFrontier filed an IND application of IMF-001 for Phase I Study in US.

Next Post ImmunoFrontier completed the CSR of Phase I Study of CHP-NY-ESO-1 in Patients with Refractory Esophageal Cancer Expressing NY-ESO 1 in Japan.

Recent Posts

ImmunoFrontier prepared the CSR of Phase I Study of CHP-NY-ESO-1 in patients with Malignancies Expressing NY-ESO 1 in US. 2013/03/29
ImmunoFrontier completed the CSR of Phase I Study of CHP-NY-ESO-1 in Patients with Refractory Esophageal Cancer Expressing NY-ESO 1 in Japan. 2012/10/17
FDA approved Phase I Study of IMF-001 in US. 2010/09/23
ImmunoFrontier filed an IND application of IMF-001 for Phase I Study in US. 2010/08/13
ImmunoFrontier filed an Application of CHP-NY-ESO-1 for Phase I Study with PMDA to develop for esophageal cancer. 2009/08/17

Challenge toward the Future of Immuno-Oncology.

Contacts

Urban Ace Higashitenma-BLDG.,1-1-19, Higashitenma,Kita-ku,Osaka,530-0044,Japan
info@immunofrontier.com

copyright © ImmunoFrontier, Inc.